Open AccessThis article is
- freely available
IL8 and Cathepsin B as Melanoma Serum Biomarkers
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Division of Hematology-Oncology, HUP, 16 Penn Tower, Philadelphia, PA 19104, USA
The Wistar Institute, 3601 Spruce St., Philadelphia, PA 19104, USA
* Author to whom correspondence should be addressed.
Received: 3 December 2010; in revised form: 15 February 2011 / Accepted: 22 February 2011 / Published: 25 February 2011
(This article belongs to the Special Issue Biomarkers
Abstract: Melanoma accounts for only a small portion of skin cancer but it is associated with high mortality. Melanoma serum biomarkers that may aid early diagnosis or guide therapy are needed clinically. However, studies of serum biomarkers have often been hampered by the serum interference that causes false readouts in immunological tests. Here we show that, after using a special buffer to eliminate the serum interference, IL-8 and cathepsin B levels were significantly elevated in melanoma patients (p < 0.05). More importantly, the combination of IL-8 and cathepsin B were also studied as a prognosis marker for melanoma mortality. Our study provides a novel approach to examine serum biomarkers.
Keywords: IL-8; cathepsin B; melanoma; serum interference
Citations to this Article
Cite This Article
MDPI and ACS Style
Zhang, H.; Fu, T.; McGettigan, S.; Kumar, S.; Liu, S.; Speicher, D.; Schuchter, L.; Xu, X. IL8 and Cathepsin B as Melanoma Serum Biomarkers. Int. J. Mol. Sci. 2011, 12, 1505-1518.
Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X. IL8 and Cathepsin B as Melanoma Serum Biomarkers. International Journal of Molecular Sciences. 2011; 12(3):1505-1518.
Zhang, Hongtao; Fu, Ting; McGettigan, Suzanne; Kumar, Suresh; Liu, Shujing; Speicher, David; Schuchter, Lynn; Xu, Xiaowei. 2011. "IL8 and Cathepsin B as Melanoma Serum Biomarkers." Int. J. Mol. Sci. 12, no. 3: 1505-1518.